전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved188 programs
AntibodyCurated CoreFDABeOne MedicinesApproved

tislelizumab (Tevimbra, BGB-A317, tislelizumab-jsgr)

Esophageal squamous cell carcinoma, gastric/GEJ adenocarcinoma, and first-line HER2-positive GEA with zanidatamab and c… · PD-1

#PD-1#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 213Status Approved
AntibodyCurated CoreFDAAmgenApproved

tarlatamab (Imdelltra, AMG 757, tarlatamab-dlle)

Extensive-stage small cell lung cancer after platinum-based chemotherapy · DLL3 × CD3

#DLL3CD3#Antibody#Approved#FDA-approved#BioJungboMoa-pick+4
Trials 39Status Approved
AntibodyLimited DatastaleMerckPhase 2

pembrolizumab or nivolumab (The combination of radiotherapy with anti-PD1, The combination of radiotherapy with anti-PD1 (pembrolizumab or nivolumab))

Melanoma · Melanoma

#Melanoma#Antibody#Phase2#Popular#monoclonal-antibody+1
Trials 185Status Active
ADCStandard DatabasestaleDaiichi Sankyoderuxtecan (Dato-DXd, Datro…Phase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Trastuzumab Deruxtecan (T-DXd) monotherapy)

Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma · Gastric Adenocarcinoma

#GastricAdenocarcinoma#ADC#Phase2#Popular#antibody-drug-conjugate+4
Trials 134Status Recruiting
ADCStandard DatabasestaleFavrillederuxtecan for metastatic b…Phase 2

Antibody-Drug Conjugate Therapy (Antibody-Drug Conjugate Therapy)

Metastatic Bladder Urothelial Carcinoma; Metastatic Renal Pelvis and Ureter Urothelial Carcinoma · FRα

#FR#ADC#Phase2#Popular#antibody-drug-conjugate+5
Trials 58Status Recruiting
CGTLimited DatastaleShenzhen Hornetcorn Bio-technol…Preclinical

CIK cell therapy (CIK cell therapy)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#CGT#Preclinical#Popular#cell-gene-therapy+4
Trials 54Status Active
AntibodyLimited DatastaleJiangsu Hansoh Pharmaceutical C…Phase 2

adebrelimab and chemotherapy (adebrelimab and chemotherapy)

Efficacy and Safety of Neoadjuvant Immunotherapy for Small Cell Lung Cancer · Efficacy and Safety of Neoadjuvant Immun

#EfficacyandSafetyofNeoadjuvantIm#Antibody#Phase2#Popular#monoclonal-antibody+1
Trials 54Status Recruiting
CGTLimited DatastaleShenzhen Hornetcorn Bio-technol…Phase 1

Autologous NK cell therapy (Autologous NK cell therapy)

NK Cell Mediated Immunity; Endometriosis · NK Cell Mediated Immunity

#NKCellMediatedImmunity#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 47Status Active
CGTLimited DatastaleVaxcell Bio, Co., Ltd.Phase 1

Autologous Natural Killer Cell Therapy (Autologous Natural Killer Cell Therapy)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 46Status Recruiting
CGTLimited DatastaleMerck Sharp & Dohme LLCPhase 2

Letermovir (Letermovir)

Cell Therapy · Cell Therapy

#CellTherapy#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 45Status Recruiting
AntibodyLimited DatastaleNew Approaches to Neuroblastoma…Phase 1

Dinutuximab (Dinutuximab)

Neuroblastoma · Neuroblastoma

#Neuroblastoma#Antibody#Phase1#monoclonal-antibody#NKcellsbyacombinatorialimmunothe+1
Trials 44Status Recruiting
CGTStandard DatabasestaleThe Methodist Hospital Research…Phase 2

gene therapy (ADV/HSV-tk, ADV/HSV-tk (gene therapy))

Glioblastoma; Anaplastic Astrocytoma · Glioblastoma

#Glioblastoma#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 42Status Recruiting
CGTStandard DatabasestaleIncyte CorporationPhase 2

Immune effector cell therapy (Immune effector cell therapy)

Cytokine Release Syndrome · Cytokine Release Syndrome

#CytokineReleaseSyndrome#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 41Status Active
AntibodyLimited DatastaleRochePhase 3

Ocrelizumab, Rituximab, Ofatumumab (Anti-CD20 therapies, Anti-CD20 therapies (Ocrelizumab, Rituximab, Ofatumumab))

Relapsing-Remitting Multiple Sclerosis (RRMS); Anti-CD20 Therapy · CD20

#CD20#Antibody#Phase3#monoclonal-antibody#Relapsing-RemittingMultipleScler+3
Trials 40Status Recruiting
CGTLimited DatastaleShanghai Unicar-Therapy Bio-med…Phase 1

CD30+ CAR T-cells (CD30+ CAR T-cells)

Classical Hodgkin Lymphoma · CD30

#CD30#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 32Status Recruiting
CGTLimited DatastaleJanssen Research & Development,…Preclinical

Cell therapy with bispecific antibodies (Cell therapy with bispecific antibodies)

Gynecological Solid Tumors · Gynecological Solid Tumors

#GynecologicalSolidTumors#CGT#Preclinical#cell-gene-therapy#CAR-T+2
Trials 32Status Recruiting
AntibodyLimited DatastaleRochePhase 2

trastuzumab (Herceptin, HER2, pyrotinib + pertuzumab/trastuzumab)

Salivary Gland Carcinoma; Precision Therapy · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#SalivaryGlandCarcinoma+2
Trials 30Status Recruiting
CGTStandard DatabasestaleBOE Technology Group Co., Ltd.Phase 2

NK cells + PD- (NK cells + PD-, NK cells + PD-(L)1 inhibitor + pemetrexed as first-line maintenance therapy)

NSCLC (Advanced Non-small Cell Lung Cancer); Colorectal Cancer · NSCLC (Advanced Non-small Cell Lung Canc

#NSCLCAdvancedNon-smallCellLungCa#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 30Status Recruiting
CGTStandard DatabasestaleKara Yakhteh Tajhiz Azma CompanyPhase 2

anti-CD19 CAR T cell therapy (anti-CD19 CAR T cell therapy)

Relapse/Refractory B-cell Acute Lymphoblastic Leukemia · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 30Status Recruiting
AntibodyLimited DatastaleEli LillyPhase 2

Toripalimab + cetuximab (3cycles, 3cycles (Toripalimab + cetuximab))

Head and Neck Squamous Cell Carcinoma; Neoadjuvant Therapy · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase2#monoclonal-antibody#NeoadjuvantTherapy+1
Trials 29Status Recruiting

1 / 10 pages

← PreviousNext →